Phase 2 clinical trials have, in fact, demonstrated that oncological treatment with mTOR-Is has permitted disease stability in ~65%−76% of patients with thyroid carcinoma of different histology (62). This evidence concerns the gene MTOR and thyroid gland carcinoma.